MSLN abundance on tumour cells is sufficient for efficient antibody targeting of doxorubicin-loaded EDVs to xenografts, resulting in suppression of tumour growth as well as reducing cell proliferation as shown by Ki67 staining of excised tumours ex vivo. The gene discussed is MKI67; the disease is neoplasm.